F2 Bioscience I 2017 Ltd - Net Worth and Insider Trading

F2 Bioscience I 2017 Ltd Net Worth

The estimated net worth of F2 Bioscience I 2017 Ltd is at least $70 Million dollars as of 2024-11-13. F2 Bioscience I 2017 Ltd is the 10% Owner of Cullinan Therapeutics Inc and owns about 4,430,964 shares of Cullinan Therapeutics Inc (CGEM) stock worth over $70 Million. Details can be seen in F2 Bioscience I 2017 Ltd's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that F2 Bioscience I 2017 Ltd has not made any transactions after 2022-06-23 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of F2 Bioscience I 2017 Ltd

F2 Bioscience I 2017 Ltd Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, F2 Bioscience I 2017 Ltd owns 1 companies in total, including Cullinan Therapeutics Inc (CGEM) .

Click here to see the complete history of F2 Bioscience I 2017 Ltd’s form 4 insider trades.

Insider Ownership Summary of F2 Bioscience I 2017 Ltd

Ticker	Comapny	Transaction Date	Type of Owner
CGEM	Cullinan Therapeutics Inc	2022-06-23	10 percent owner

F2 Bioscience I 2017 Ltd Latest Holdings Summary

F2 Bioscience I 2017 Ltd currently owns a total of 1 stock. F2 Bioscience I 2017 Ltd owns 4,430,964 shares of Cullinan Therapeutics Inc (CGEM) as of June 23, 2022, with a value of $70 Million.

Latest Holdings of F2 Bioscience I 2017 Ltd

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
CGEM	Cullinan Therapeutics Inc	2022-06-23	4,430,964	15.80	69,987,076

Holding Weightings of F2 Bioscience I 2017 Ltd

F2 Bioscience I 2017 Ltd Form 4 Trading Tracker

According to the SEC Form 4 filings, F2 Bioscience I 2017 Ltd has made a total of 1 transactions in Cullinan Therapeutics Inc (CGEM) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Cullinan Therapeutics Inc is the sale of 101,903 shares on June 23, 2022, which brought F2 Bioscience I 2017 Ltd around $1 Million.

Insider Trading History of F2 Bioscience I 2017 Ltd

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

F2 Bioscience I 2017 Ltd Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

F2 Bioscience I 2017 Ltd Ownership Network

Ownership Network List of F2 Bioscience I 2017 Ltd

No Data

Ownership Network Relation of F2 Bioscience I 2017 Ltd

F2 Bioscience I 2017 Ltd Owned Company Details

What does Cullinan Therapeutics Inc do?

Who are the key executives at Cullinan Therapeutics Inc?

F2 Bioscience I 2017 Ltd is the 10 percent owner of Cullinan Therapeutics Inc. Other key executives at Cullinan Therapeutics Inc include See Remarks Jennifer Michaelson , Acting Chief Business Officer Savill Corrine , and director & President and CEO Nadim Ahmed .

Cullinan Therapeutics Inc (CGEM) Insider Trades Summary

Over the past 18 months, F2 Bioscience I 2017 Ltd made no insider transaction in Cullinan Therapeutics Inc (CGEM). Other recent insider transactions involving Cullinan Therapeutics Inc (CGEM) include a net sale of 102,710 shares made by Jennifer Michaelson , a net sale of 5,361 shares made by Jeffrey Trigilio , and a net sale of 3,027 shares made by Jeffrey Alan Jones .

In summary, during the past 3 months, insiders sold 16,000 shares of Cullinan Therapeutics Inc (CGEM) in total and bought 0 shares, with a net sale of 16,000 shares. During the past 18 months, 239,108 shares of Cullinan Therapeutics Inc (CGEM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 239,108 shares.

Cullinan Therapeutics Inc (CGEM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cullinan Therapeutics Inc Insider Transactions

No Available Data

F2 Bioscience I 2017 Ltd Mailing Address

Above is the net worth, insider trading, and ownership report for F2 Bioscience I 2017 Ltd. You might contact F2 Bioscience I 2017 Ltd via mailing address: 8, Rue Saint-leger, Geneva V8 Ch 1205.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.